Mary H. Hanlon

1.6k total citations · 1 hit paper
27 papers, 1.3k citations indexed

About

Mary H. Hanlon is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Mary H. Hanlon has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Infectious Diseases and 7 papers in Oncology. Recurrent topics in Mary H. Hanlon's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and Biochemical and Molecular Research (5 papers). Mary H. Hanlon is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and Biochemical and Molecular Research (5 papers). Mary H. Hanlon collaborates with scholars based in United States, United Kingdom and India. Mary H. Hanlon's co-authors include Marion Lohrum, Karen H. Vousden, Robert L. Ludwig, Michael H.G. Kubbutat, Linda Sealy, Robert Ferone, David Porter, Linda M. Bundy, Eric S. Furfine and Thomas W. Sturgill and has published in prestigious journals such as Journal of Biological Chemistry, The EMBO Journal and Biochemistry.

In The Last Decade

Mary H. Hanlon

27 papers receiving 1.3k citations

Hit Papers

Regulation of HDM2 activity by the ribosomal protein L11 2003 2026 2010 2018 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regulation of HDM2 activity by the ribosomal protein L11
    2003 521 citations Marion Lohrum, Robert L. Ludwig et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary H. Hanlon United States 17 925 448 283 210 143 27 1.3k
Birgitte Munch‐Petersen Denmark 23 1.2k 1.3× 385 0.9× 274 1.0× 78 0.4× 227 1.6× 77 1.8k
Himadri Samanta United States 19 676 0.7× 244 0.5× 298 1.1× 268 1.3× 116 0.8× 35 1.2k
Russell K. Young United States 11 533 0.6× 392 0.9× 301 1.1× 298 1.4× 81 0.6× 11 1.3k
Michael A. Milhollen United States 14 1.5k 1.6× 538 1.2× 173 0.6× 48 0.2× 299 2.1× 26 1.9k
Charles Garrett United States 9 1.2k 1.3× 209 0.5× 181 0.6× 52 0.2× 175 1.2× 10 1.5k
Paul Tawa United States 17 695 0.8× 175 0.4× 116 0.4× 87 0.4× 99 0.7× 48 1.2k
Helen Yu United States 19 1.3k 1.4× 297 0.7× 268 0.9× 217 1.0× 232 1.6× 26 2.0k
Chen‐Chen Kan United States 12 604 0.7× 241 0.5× 79 0.3× 57 0.3× 201 1.4× 15 898
Michael S. Boosalis United States 23 1.7k 1.9× 137 0.3× 248 0.9× 107 0.5× 104 0.7× 37 2.1k
Hidekazu Sawada Japan 11 602 0.7× 245 0.5× 271 1.0× 480 2.3× 117 0.8× 25 1.3k

Countries citing papers authored by Mary H. Hanlon

Since Specialization
Citations

This map shows the geographic impact of Mary H. Hanlon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary H. Hanlon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary H. Hanlon more than expected).

Fields of papers citing papers by Mary H. Hanlon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary H. Hanlon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary H. Hanlon. The network helps show where Mary H. Hanlon may publish in the future.

Co-authorship network of co-authors of Mary H. Hanlon

This figure shows the co-authorship network connecting the top 25 collaborators of Mary H. Hanlon. A scholar is included among the top collaborators of Mary H. Hanlon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary H. Hanlon. Mary H. Hanlon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haffner, Curt D., Aaron B. Miller, Robert A. Reid, et al.. (2008). Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP). Bioorganic & Medicinal Chemistry Letters. 18(15). 4360–4363. 47 indexed citations
2.
3.
Miller, John F., C. Webster Andrews, Eric S. Furfine, et al.. (2006). Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorganic & Medicinal Chemistry Letters. 16(7). 1788–1794. 70 indexed citations
4.
Miller, John F., Eric S. Furfine, Mary H. Hanlon, et al.. (2004). Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorganic & Medicinal Chemistry Letters. 14(4). 959–963. 16 indexed citations
5.
Hanlon, Mary H., David Porter, Eric S. Furfine, et al.. (2004). Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1 Proteases by GW0385 and Other Arylsulfonamides. Biochemistry. 43(45). 14500–14507. 14 indexed citations
6.
Lohrum, Marion, Robert L. Ludwig, Michael H.G. Kubbutat, Mary H. Hanlon, & Karen H. Vousden. (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 3(6). 577–587. 521 indexed citations breakdown →
7.
8.
Hanlon, Mary H., et al.. (2001). Characterization of C/EBPβ isoforms in normal versus neoplastic mammary epithelial cells. Journal of Cellular Physiology. 189(1). 91–105. 61 indexed citations
9.
Porter, David, Mary H. Hanlon, & Eric S. Furfine. (2001). HIV-1 Protease:  Characterization of a Catalytically Competent Enzyme−Substrate Intermediate. Biochemistry. 41(4). 1302–1307. 9 indexed citations
10.
Porter, David, et al.. (2001). Effectors of HIV-1 Protease Peptidolytic Activity. Biochemistry. 40(37). 11131–11139. 12 indexed citations
11.
Dixon, Eric P., G Pahel, Warren J. Rocque, et al.. (2000). The E1 Helicase of Human Papillomavirus Type 11 Binds to the Origin of Replication with Low Sequence Specificity. Virology. 270(2). 345–357. 21 indexed citations
12.
Hanlon, Mary H., Linda M. Bundy, & Linda Sealy. (2000). C/EBPBeta and Elk-1 synergistically transactivate the c-fos serum response element. BMC Cell Biology. 1(1). 2–2. 25 indexed citations
13.
Hanlon, Mary H. & Linda Sealy. (1999). Ras Regulates the Association of Serum Response Factor and CCAAT/Enhancer-binding Protein β. Journal of Biological Chemistry. 274(20). 14224–14228. 35 indexed citations
14.
Porter, David, Steven A. Short, Mary H. Hanlon, et al.. (1998). Product Release Is the Major Contributor tok cat for the Hepatitis C Virus Helicase-catalyzed Strand Separation of Short Duplex DNA. Journal of Biological Chemistry. 273(30). 18906–18914. 48 indexed citations
15.
Hanlon, Mary H., Robert Ferone, Kurt Weaver, & Paul H. Ray. (1994). Enzymatic Synthesis of Folate and Antifolate Polyglutamates with Escherichia coli Folylpolyglutamate Synthetase. Analytical Biochemistry. 216(2). 345–351. 4 indexed citations
16.
Ferone, Robert, et al.. (1993). Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89. 34. 274. 5 indexed citations
17.
Duch, David S., et al.. (1991). Studies on the mechanism of antitumor action of 2-desamino-2-methyl-5,8-dideazaisofolic acid. Biochemical Pharmacology. 41(5). 781–787. 13 indexed citations
18.
Comley, John C.W., et al.. (1991). Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrobial Agents and Chemotherapy. 35(10). 1965–1974. 25 indexed citations
19.
Kelley, James L., Ed W. McLean, Mark Edelstein, et al.. (1990). Synthesis and biological activity of an acyclic analog of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl]amino]benzoyl]-L-glutamic acid. Journal of Medicinal Chemistry. 33(2). 561–567. 24 indexed citations
20.
Hanlon, Mary H., Robert Ferone, Robert J. Mullin, & Barry R. Keith. (1990). In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.. PubMed. 50(11). 3207–11. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Birgitte Munch‐Petersen Breakdown of academic impact, for papers by Himadri Samanta Breakdown of academic impact, for papers by Russell K. Young Breakdown of academic impact, for papers by Michael A. Milhollen Breakdown of academic impact, for papers by Charles Garrett Breakdown of academic impact, for papers by Paul Tawa Breakdown of academic impact, for papers by Helen Yu Breakdown of academic impact, for papers by Chen‐Chen Kan Breakdown of academic impact, for papers by Michael S. Boosalis Breakdown of academic impact, for papers by Hidekazu Sawada
Rankless by CCL
2026